XML 76 R62.htm IDEA: XBRL DOCUMENT v3.20.4
Acquisitions - Narrative (Details)
$ / shares in Units, $ in Thousands, € in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Dec. 10, 2020
USD ($)
Dec. 10, 2020
EUR (€)
Oct. 23, 2020
USD ($)
Apr. 07, 2020
USD ($)
$ / shares
Sep. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
Jun. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 10, 2020
EUR (€)
Business Acquisition [Line Items]                      
Acquired in-process research and development expenses               $ 5,856,000 $ 4,251,000 $ 0  
Stock-based compensation expense               $ 643,000 $ 636,000 $ 845,000  
Discount rate of acquired IPR&D           8.00%   8.00% 9.50%    
Foreign currency exchange rate           1.2   1.2      
Three year senior unsecured term loan facility | Medium-term notes                      
Business Acquisition [Line Items]                      
Borrowing under the senior unsecured term loan facility         $ 1,000,000            
Immunomedics, Inc.                      
Business Acquisition [Line Items]                      
Revenue since acquisition date               $ 49,000      
Consideration     $ 20,600,000                
Accelerated stock-based expense               289,000      
Acquisition-related expenses           $ 615,000   39,000      
Fair value step-up adjustment of inventories acquired     881,000                
Inventories     946,000                
Liability related to future royalties     1,100,000                
Goodwill     $ 3,991,000                
Immunomedics, Inc. | Measurement Input, Risk Free Interest Rate                      
Business Acquisition [Line Items]                      
Liability related to future royalties, measurement Input     0.025                
Immunomedics, Inc. | Measurement Input, Expected Term                      
Business Acquisition [Line Items]                      
Liability related to future royalties, measurement Input     16                
Immunomedics, Inc. | Payments to outstanding common stockholders                      
Business Acquisition [Line Items]                      
Cash payments made for acquisition     $ 20,400,000                
Immunomedics, Inc. | Payments to equity award holders                      
Business Acquisition [Line Items]                      
Cash payments made for acquisition     242,000                
Immunomedics, Inc. | Acquired IPR&D                      
Business Acquisition [Line Items]                      
Acquired IPR&D     $ 15,760,000                
Discount rate of acquired IPR&D     7.00%                
Immunomedics, Inc. | Intangible asset - Trodelvy for mTNBC                      
Business Acquisition [Line Items]                      
Finite-lived intangible asset     $ 4,600,000                
Discount rate of finite-lived intangible asset acquired     7.00%                
Estimated useful life of finite-lived intangible asset acquired     12 years                
Immunomedics, Inc. | Outlicense contract                      
Business Acquisition [Line Items]                      
Finite-lived intangible asset     $ 175,000                
Discount rate of finite-lived intangible asset acquired     7.00%                
Estimated useful life of finite-lived intangible asset acquired     15 years                
MYR                      
Business Acquisition [Line Items]                      
Consideration $ 1,400,000 € 1,200                  
Maximum potential future milestone payments $ 360,000                   € 300
Forty Seven, Inc.                      
Business Acquisition [Line Items]                      
Share price | $ / shares       $ 95.50              
Total consideration, net of acquired cash       $ 4,700,000              
Acquired in-process research and development expenses       4,500,000     $ 4,500,000        
Assets acquired       $ 202,000              
Accelerated stock-based expense               $ 144,000